Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 65

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...

Targeting receptor tyrosine kinase signalling pathways in DIPG by using ...

Diffuse Intrinsic Pontine Glioma (DIPG) is the most dismal paediatric brain tumour, characterised by universal mortality and an average survival of less than one year. Several factors contribute to the unique challenges in treating DIPG, including localisation, infiltrative pattern of growth and chemoresistance. Treatment options are limited to palliative radiotherapy. ...

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an ...

Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises in the brainstem of children predominantly between the ages of 6 and 9.  Unlike many brain tumors, DIPGs cannot be removed through surgery due to its sensitive location. The standard of care today remains radiation therapy (...

Targeting the thioredoxin system as a novel strategy for DIPG

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive of all childhood brain cancers. Radiotherapy treatment is palliative, and chemotherapy is ineffective. We have found that both DIPG cells and DIPG animal models are exquisitely sensitive to auranofin. Auranofin is a gold containing anti-inflammatory compound previously used to treat rheumatoid ...

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...